Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity , Bardet-Biedl Syndrome and Prader-Willi Syndrome at ENDO 2026
 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome at ENDO 2026
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
Rhythm Pharmaceuticals Announces IMCIVREE® Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
QIMC Reports Multiple Elevated Hydrogen Mud-Gas Readings Over 100m-250m Interval of DDH-26-04, Including a Peak Hydrogen Reading of 16.0%, Two Hydrogen Readings of 13.5%, and Nine Readings at or Above 5% Hydrogen
Oreterra Completes Airborne Geophysical Survey of the Kinkaid Cu-Au-Ag Project, Nevada, Identifies Significant New Porphyry Target
